Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab

Michele Corrado, Melissa Bersanelli, Letizia Gnetti, Cinzia Azzoni, Lorena Bottarelli, Nicola Sverzellati, Nicoletta Campanini, Elena Varotti, Raffaele Parziale, Elena Rapacchi, Giuseppe Caruso, Francesco Leonardi, Enrico Maria Silini, Sebastiano Buti

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aim: We studied the possible clinical significance of loss of heterozygosity (LOH) at key tumor suppressor genes loci in advanced renal cancer patients treated with nivolumab. Methods: LOH study was performed on 3p14.2 (FHIT gene); 3p21.3-21.2; 9p21 (BDMF gene); 9p22 (SH3GL2 gene). Results: Of 12 patients, 8 (67%) had LOH. The most affected gene was FHIT. All five patients with LOH at FHIT locus had good outcome, mean progression free survival of 6.8 months. The patients LOH negative at FHIT locus had mean progression free survival of 4 months, 67% were treatment refractory. Overall, 75% of patients with LOH of at least one gene had benefit; 75% of LOH negative cases were refractory. Conclusion: LOH at key tumor suppressor genes should be further investigated as predictive for immunotherapy.
Original languageEnglish
Pages (from-to)743-752
Number of pages10
JournalImmunotherapy
Volume10
DOIs
Publication statusPublished - 2018

Keywords

  • FHIT
  • loss of heterozygosity
  • renal cell carcinoma

Fingerprint

Dive into the research topics of 'Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab'. Together they form a unique fingerprint.

Cite this